AU2017376960B2 - Micafungin compositions - Google Patents

Micafungin compositions Download PDF

Info

Publication number
AU2017376960B2
AU2017376960B2 AU2017376960A AU2017376960A AU2017376960B2 AU 2017376960 B2 AU2017376960 B2 AU 2017376960B2 AU 2017376960 A AU2017376960 A AU 2017376960A AU 2017376960 A AU2017376960 A AU 2017376960A AU 2017376960 B2 AU2017376960 B2 AU 2017376960B2
Authority
AU
Australia
Prior art keywords
micafungin
compositions
aqueous pharmaceutical
imp
parenteral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017376960A
Other languages
English (en)
Other versions
AU2017376960A1 (en
Inventor
Sydney J. Cope
Mark J. Doty
Christine L. Rebbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of AU2017376960A1 publication Critical patent/AU2017376960A1/en
Application granted granted Critical
Publication of AU2017376960B2 publication Critical patent/AU2017376960B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017376960A 2016-12-16 2017-12-15 Micafungin compositions Active AU2017376960B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435695P 2016-12-16 2016-12-16
US62/435,695 2016-12-16
PCT/US2017/066652 WO2018112330A1 (en) 2016-12-16 2017-12-15 Micafungin compositions

Publications (2)

Publication Number Publication Date
AU2017376960A1 AU2017376960A1 (en) 2019-05-23
AU2017376960B2 true AU2017376960B2 (en) 2023-12-14

Family

ID=60972375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017376960A Active AU2017376960B2 (en) 2016-12-16 2017-12-15 Micafungin compositions

Country Status (11)

Country Link
US (2) US12403173B2 (enExample)
EP (1) EP3554474B1 (enExample)
JP (2) JP2020510619A (enExample)
AU (1) AU2017376960B2 (enExample)
DK (1) DK3554474T3 (enExample)
ES (1) ES2972008T3 (enExample)
FI (1) FI3554474T3 (enExample)
HU (1) HUE066069T2 (enExample)
PL (1) PL3554474T3 (enExample)
PT (1) PT3554474T (enExample)
WO (1) WO2018112330A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111044636A (zh) * 2019-12-30 2020-04-21 卓和药业集团有限公司 米卡芬净含量的分析方法
US20220040092A1 (en) * 2020-06-27 2022-02-10 RK Pharma Solutions LLC Ready to use injectable formulations of Micafungin Sodium
CN112710753A (zh) * 2020-12-18 2021-04-27 卓和药业集团有限公司 米卡芬净有关物质的分析方法
WO2024233925A1 (en) * 2023-05-11 2024-11-14 Hikma Pharmaceuticals Usa Inc. Stable micafungin compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102512379A (zh) * 2011-12-16 2012-06-27 深圳市健元医药科技有限公司 一种新型棘白菌素类抗真菌药物组合物及其制备方法
US20130338060A1 (en) * 2011-01-31 2013-12-19 Shanghai Techwell Biopharmaceutical Co., Ltd Liquid medicinal composition containing echinocandin antifungal agent micafungin
WO2016107890A1 (en) * 2014-12-31 2016-07-07 Galenicum Health S.L. Stable pharmaceutical compositions comprising micafungin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
MX9702531A (es) 1994-10-07 1997-06-28 Fujisawa Pharmaceutical Co Compuesto nuevo.
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
CN103360486A (zh) 2004-08-18 2013-10-23 诺瓦生命科学有限公司 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽
WO2008137128A2 (en) 2007-05-03 2008-11-13 Northeastern University Methods of treating fungal infections
AU2013254940A1 (en) 2008-04-21 2014-01-16 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MX2010012451A (es) 2008-05-15 2010-12-07 Baxter Int Formulaciones farmaceuticas estables.
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US20110071072A1 (en) * 2009-08-28 2011-03-24 Georgetown University, A Congressionally Chartered Institution Of Higher Education Antifungal Bone Cements
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
CN108290845B (zh) * 2015-10-07 2021-08-03 大日本住友制药株式会社 嘧啶化合物
IN2015MU03858A (enExample) * 2015-10-10 2015-10-23 Gufic Biosciences Ltd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130338060A1 (en) * 2011-01-31 2013-12-19 Shanghai Techwell Biopharmaceutical Co., Ltd Liquid medicinal composition containing echinocandin antifungal agent micafungin
CN102512379A (zh) * 2011-12-16 2012-06-27 深圳市健元医药科技有限公司 一种新型棘白菌素类抗真菌药物组合物及其制备方法
WO2016107890A1 (en) * 2014-12-31 2016-07-07 Galenicum Health S.L. Stable pharmaceutical compositions comprising micafungin

Also Published As

Publication number Publication date
JP2020510619A (ja) 2020-04-09
US20250345386A1 (en) 2025-11-13
US20180169180A1 (en) 2018-06-21
HUE066069T2 (hu) 2024-07-28
EP3554474B1 (en) 2023-12-06
FI3554474T3 (fi) 2024-02-21
DK3554474T3 (da) 2024-02-19
PL3554474T3 (pl) 2024-04-15
WO2018112330A1 (en) 2018-06-21
AU2017376960A1 (en) 2019-05-23
PT3554474T (pt) 2024-02-12
JP2024012211A (ja) 2024-01-25
ES2972008T3 (es) 2024-06-10
EP3554474A1 (en) 2019-10-23
US12403173B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
US20250345386A1 (en) Micafungin compositions
US7985757B2 (en) Argatroban formulation
AU2013261012B2 (en) Ready to be infused gemcitabine solution
CZ20023825A3 (cs) Formulace esmololu
EP3906917B1 (en) Formulations of vancomycin with glycerol
KR101487953B1 (ko) 유기용매 무함유 젬시타빈 수용액 조성물
WO2020160123A1 (en) Levothyroxine liquid formulations
WO2024100679A1 (en) Parenteral formulations of flucytosine
WO2024142091A1 (en) Stable aqueous injectable formulation of flucytosine
WO2025160344A1 (en) Micafungin formulations
WO2024233925A1 (en) Stable micafungin compositions

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee
FGA Letters patent sealed or granted (standard patent)
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 14 APR 2024